Development of peptidic MERS-CoV entry inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1513-1519, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-320049
ABSTRACT
In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Antivirais
/
Peptídeos
/
Farmacologia
/
Fisiologia
/
Desenho de Fármacos
/
Infecções por Coronavirus
/
Dipeptidil Peptidase 4
/
Tratamento Farmacológico
/
Internalização do Vírus
/
Glicoproteína da Espícula de Coronavírus
Limite:
Humanos
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS